Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adalimumab biosimilar - Fujifilm Kyowa Kirin Biologics

Drug Profile

Adalimumab biosimilar - Fujifilm Kyowa Kirin Biologics

Alternative Names: FKB-327; Hulio

Latest Information Update: 03 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FUJIFILM Corporation - Kyowa Hakko Kirin (JV); Fujifilm Kyowa Kirin Biologics
  • Developer Biocon; Fujifilm Kyowa Kirin Biologics; Viatris Inc
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Monoclonal antibodies; Nootropics; Skin disorder therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunosuppressants; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ankylosing spondylitis; Axial spondyloarthritis; Behcet's syndrome; Crohn's disease; Hidradenitis suppurativa; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Pustular psoriasis; Rheumatoid arthritis; Ulcerative colitis; Uveitis

Most Recent Events

  • 03 Aug 2023 Launched for Ankylosing spondylitis (In adults) in Germany, Finland, Ireland, Switzerland, Sweden, Portugal, Poland, Netherlands, Austria, Spain, Czech Republic (SC) (Biocon website, August 2023)
  • 03 Aug 2023 Launched for Axial spondyloarthritis (In adults) in France, Germany, Sweden, Netherlands, Poland, Austria, Canada, Spain, Czech Republic (SC) (Biocon website, August 2023)
  • 03 Aug 2023 Launched for Crohn's disease (In adolescents, In children, In adults) in Germany, Switzerland, Sweden, Poland, Austria, Spain (SC) (Biocon website, August 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top